search
Back to results

Study to Evaluate Improvements of the Quality of Sleep With NOVANUIT® Triple Action in Healthy Volunteers With Sleep Disorders

Primary Purpose

Sleep Disorder (Healthy Volunteers)

Status
Completed
Phase
Phase 1
Locations
Poland
Study Type
Interventional
Intervention
MELATONIN (MELATL07959)
Sponsored by
Sanofi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sleep Disorder (Healthy Volunteers)

Eligibility Criteria

20 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion criteria :

  • Healthy men or women volunteers, aged from 20 to 75 years included at the moment of the inclusion visit.
  • Subject with Body Mass Index (BMI) between 18.5 and 29.9 kg/m² (limits included).
  • Good general health (based on subject interview about his/her medical history and on clinical exam realized by investigator).
  • Subject willing to follow diet recommendations in accordance with hygiene and dietary advice defined in the protocol.
  • Subject suffering from mild to moderate sleep disorders assessed by Insomnia Severity Index (ISI) questionnaire completed during the selection and presenting a score between 7 and 22 (limits excluded).
  • Subject covered by a social security or insurance.

Exclusion criteria:

  • Subject having consumed medications for sleep disorders (sleeping pills) during the 6 months previous the inclusion visit and throughout the study duration.
  • Subject having consumed dietary supplements for sleep disorders during the 3 months previous to inclusion visit and throughout the study duration.
  • Subject presenting history of severe chronic disease (cancer, HIV, renal or hepatic failure, hepatic disorders, inflammatory digestive and known malabsorption diseases, arthritis or chronic respiratory insufficiency, etc.) found to be inconsistent for the study follow up by investigator.
  • Subject suffering from a chronic or acute pathology causing sleep disorders.
  • Subject consuming products with impact on sleep deterioration at the moment of inclusion visit and throughout the study duration, belong to investigator.
  • Subject having undergone general anesthesia during the month previous to inclusion visit.
  • Subject suffering from eating disorders (anorexia, bulimia, etc.).
  • Subject consuming more than 1.5 packet of tobacco per day (30 cigarettes/day or 27 mg of nicotine/day in electronic cigarette).
  • Subject with history of known dependency to drugs or alcohol (consuming more than 3 alcohol units per day). In this study, 1 unit of alcohol is defined as 250 mL of beer, 100 mL of wine or 30 mL of spirits.
  • Subject having under the care a child who as constant sleep troubles through the night.
  • Subject with irregular working hours (day/night shifts, day/night duties, work trip during the study, etc.).
  • Subject taking part in another clinical trial simultaneously and/or in the month previous to inclusion visit and/or being in exclusion period of a previous clinical trial.
  • Woman planning to be pregnant soon, actually pregnant or lactating.
  • Woman without efficient contraceptive method such as: hormonal contraception (including patch, contraceptive ring, etc.), uterine device or any other mechanic contraceptive method, or condom or diaphragm or spermicide, throughout the duration of the study.
  • Subject with sensitivity or known allergy to the product used in the study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Sites / Locations

  • Sanofi Administrative Office

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Novanuit® Triple Action

Arm Description

2 capsules of Novanuit® Triple Action once daily for 2 weeks, 30 minutes to 1 hour before bedtime.

Outcomes

Primary Outcome Measures

Comparison of the sleep quality
Difference in the average score of sleep quality

Secondary Outcome Measures

Comparison of the average scores of sleep quality
Difference in the average score of sleep quality
Comparison of time for getting asleep
Difference in the average score of time for getting asleep
Comparison of sleep time
Difference in the average score of sleep time
Comparison of number of nocturnal awakening
Difference in the average score of number of nocturnal awakening
Comparison of number of nightmares
Difference in the average score of number of nightmares
Comparison of awakening quality
Difference in the average score of awakening quality
Comparison of mean tiredness
Difference in the average score of mean tiredness
Adverse events (AEs)
Number of participants with AEs
Dependency questionnaire
Assessment of product's effects dependency at Day 28

Full Information

First Posted
April 20, 2018
Last Updated
April 21, 2022
Sponsor
Sanofi
search

1. Study Identification

Unique Protocol Identification Number
NCT03514732
Brief Title
Study to Evaluate Improvements of the Quality of Sleep With NOVANUIT® Triple Action in Healthy Volunteers With Sleep Disorders
Official Title
An Open Label, Single Arm, Exploratory Study to Estimate the Range of Improvement of the Quality of Sleep With NOVANUIT® Triple Action in Subjects With Mild to Moderate Sleep Disorders
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
March 17, 2017 (Actual)
Primary Completion Date
July 5, 2017 (Actual)
Study Completion Date
July 5, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Primary Objective: To estimate the range of improvement of NOVANUIT® triple action on sleep quality global score. Secondary Objectives: To estimate the range of improvement of NOVANUIT® triple action on following parameters: time for getting asleep, sleep time, number of nocturnal awakening, number of nightmares, sleep quality (score from 0 to 10), and mean tiredness during the day (score from 0 to 10). To estimate persistency of NOVANUIT® triple action effects after end of study product consumption. To assess dependency to NOVANUIT® triple action after study product cessation. To assess tolerance of NOVANUIT® triple action during the study.
Detailed Description
Study participation duration for each participant will be 4 weeks including a 2-week treatment period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep Disorder (Healthy Volunteers)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Novanuit® Triple Action
Arm Type
Experimental
Arm Description
2 capsules of Novanuit® Triple Action once daily for 2 weeks, 30 minutes to 1 hour before bedtime.
Intervention Type
Drug
Intervention Name(s)
MELATONIN (MELATL07959)
Intervention Description
Pharmaceutical form:Capsule Route of administration: Oral
Primary Outcome Measure Information:
Title
Comparison of the sleep quality
Description
Difference in the average score of sleep quality
Time Frame
From baseline to Day 21
Secondary Outcome Measure Information:
Title
Comparison of the average scores of sleep quality
Description
Difference in the average score of sleep quality
Time Frame
From baseline to Day 28
Title
Comparison of time for getting asleep
Description
Difference in the average score of time for getting asleep
Time Frame
From baseline to Day 28
Title
Comparison of sleep time
Description
Difference in the average score of sleep time
Time Frame
From baseline to Day 28
Title
Comparison of number of nocturnal awakening
Description
Difference in the average score of number of nocturnal awakening
Time Frame
From baseline to Day 28
Title
Comparison of number of nightmares
Description
Difference in the average score of number of nightmares
Time Frame
From baseline to Day 28
Title
Comparison of awakening quality
Description
Difference in the average score of awakening quality
Time Frame
From baseline to Day 28
Title
Comparison of mean tiredness
Description
Difference in the average score of mean tiredness
Time Frame
From baseline to Day 28
Title
Adverse events (AEs)
Description
Number of participants with AEs
Time Frame
From baseline to Day 28
Title
Dependency questionnaire
Description
Assessment of product's effects dependency at Day 28
Time Frame
At Day 28

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria : Healthy men or women volunteers, aged from 20 to 75 years included at the moment of the inclusion visit. Subject with Body Mass Index (BMI) between 18.5 and 29.9 kg/m² (limits included). Good general health (based on subject interview about his/her medical history and on clinical exam realized by investigator). Subject willing to follow diet recommendations in accordance with hygiene and dietary advice defined in the protocol. Subject suffering from mild to moderate sleep disorders assessed by Insomnia Severity Index (ISI) questionnaire completed during the selection and presenting a score between 7 and 22 (limits excluded). Subject covered by a social security or insurance. Exclusion criteria: Subject having consumed medications for sleep disorders (sleeping pills) during the 6 months previous the inclusion visit and throughout the study duration. Subject having consumed dietary supplements for sleep disorders during the 3 months previous to inclusion visit and throughout the study duration. Subject presenting history of severe chronic disease (cancer, HIV, renal or hepatic failure, hepatic disorders, inflammatory digestive and known malabsorption diseases, arthritis or chronic respiratory insufficiency, etc.) found to be inconsistent for the study follow up by investigator. Subject suffering from a chronic or acute pathology causing sleep disorders. Subject consuming products with impact on sleep deterioration at the moment of inclusion visit and throughout the study duration, belong to investigator. Subject having undergone general anesthesia during the month previous to inclusion visit. Subject suffering from eating disorders (anorexia, bulimia, etc.). Subject consuming more than 1.5 packet of tobacco per day (30 cigarettes/day or 27 mg of nicotine/day in electronic cigarette). Subject with history of known dependency to drugs or alcohol (consuming more than 3 alcohol units per day). In this study, 1 unit of alcohol is defined as 250 mL of beer, 100 mL of wine or 30 mL of spirits. Subject having under the care a child who as constant sleep troubles through the night. Subject with irregular working hours (day/night shifts, day/night duties, work trip during the study, etc.). Subject taking part in another clinical trial simultaneously and/or in the month previous to inclusion visit and/or being in exclusion period of a previous clinical trial. Woman planning to be pregnant soon, actually pregnant or lactating. Woman without efficient contraceptive method such as: hormonal contraception (including patch, contraceptive ring, etc.), uterine device or any other mechanic contraceptive method, or condom or diaphragm or spermicide, throughout the duration of the study. Subject with sensitivity or known allergy to the product used in the study. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Sciences & Operations
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
Sanofi Administrative Office
City
Gdańsk
Country
Poland

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Learn more about this trial

Study to Evaluate Improvements of the Quality of Sleep With NOVANUIT® Triple Action in Healthy Volunteers With Sleep Disorders

We'll reach out to this number within 24 hrs